Publications by authors named "M Gheorghiu"
Pharmacological management of pituitary adenomas - what is new on the horizon?
Expert Opin Pharmacother
January 2025
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours that originate from chromaffin cells and occur in the adrenal medulla and in the sympathetic or parasympathetic ganglia. Nearly 70% of PPGLs result from germline or somatic mutations in a single driver gene. The aim of this study was to characterize the genetic background and clinical characteristics related to genetic profile of patients with PPGLs from Romania.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted in Romania to assess iodine levels in schoolchildren and neonates after 20 years of mandatory iodized salt use, involving 1352 children and 18,349 neonates for data collection.
- The results indicated that the median urinary iodine concentration (mUIC) in schoolchildren was adequate, with 62% of households using iodized salt; however, neonates showed a concerning 14.7% of high TSH levels, highlighting potential iodine deficiency in pregnant women.
- The conclusion emphasizes the need for improved iodized salt usage (currently below the recommended 90%) and greater public awareness regarding the health impacts of iodine deficiency, particularly for children's development.
Background: The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. We assessed whether flecainide is effective to prevent AA during the first 3 months after PFO closure, and whether 6 months of treatment with flecainide is more effective than 3 months to prevent AA after PFO closure.
Methods: AFLOAT (Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia Trial) is a prospective, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the end points (PROBE [Prospective Randomized Open, Blinded End Point] design).
It is widely known that diabetes mellitus negatively impacts both the innate immunity (the inflammatory response) and the acquired immunity (the humoral and cellular immune responses). Many patients with diabetes go on to develop chronic kidney disease, which will necessitate hemodialysis. In turn, long-term chronic hemodialysis generates an additional chronic inflammatory response and impairs acquired immunity.
View Article and Find Full Text PDF